DHR News & Events

Reports Q1 revenue $6B, consensus $6B. Rainer Blair, President and CEO, stated, "Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth. On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid. We were also pleased to announce our intention to acquire Masimo Corporation, a leading provider of mission-critical pulse oximetry and patient monitoring solutions in acute care settings. We believe there are clear opportunities to enhance Masimo's performance through DBS and our global scale. Looking ahead, the strength of our balance sheet and free cash flow generation provides additional capacity for value-creating capital deployment."

Consensus $8.40. For full year 2026, the Company continues to expect that non-GAAP core revenue will increase in the 3% to 6% range year-over-year, consensus $25.62B. The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.35 to $8.55 versus previous guidance of $8.35 to $8.50.

For the second quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.